- Home
- PHAR vs GRAL Comparison
PHAR vs GRAL Comparison
Compare PHAR & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- GRAL
- Stock Information
- Founded
- PHAR 1988
- GRAL 2016
- Country
- PHAR Netherlands
- GRAL United States
- Employees
- PHAR N/A
- GRAL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- PHAR Health Care
- GRAL
- Exchange
- PHAR Nasdaq
- GRAL NYSE
- Market Cap
- PHAR 731.1M
- GRAL 1.3B
- IPO Year
- PHAR N/A
- GRAL N/A
- Fundamental
- Price
- PHAR $9.88
- GRAL $44.85
- Analyst Decision
- PHAR Strong Buy
- GRAL Buy
- Analyst Count
- PHAR 3
- GRAL 3
- Target Price
- PHAR $30.00
- GRAL $31.50
- AVG Volume (30 Days)
- PHAR 4.3K
- GRAL 1.5M
- Earning Date
- PHAR 07-31-2025
- GRAL 08-12-2025
- Dividend Yield
- PHAR N/A
- GRAL N/A
- EPS Growth
- PHAR N/A
- GRAL N/A
- EPS
- PHAR N/A
- GRAL N/A
- Revenue
- PHAR $320,708,000.00
- GRAL $130,711,000.00
- Revenue This Year
- PHAR $13.31
- GRAL $19.52
- Revenue Next Year
- PHAR $7.68
- GRAL $20.37
- P/E Ratio
- PHAR N/A
- GRAL N/A
- Revenue Growth
- PHAR 24.13
- GRAL 30.47
- 52 Week Low
- PHAR $6.65
- GRAL $12.33
- 52 Week High
- PHAR $12.61
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- PHAR 40.64
- GRAL N/A
- Support Level
- PHAR $10.46
- GRAL N/A
- Resistance Level
- PHAR $11.49
- GRAL N/A
- Average True Range (ATR)
- PHAR 0.31
- GRAL 0.00
- MACD
- PHAR -0.16
- GRAL 0.00
- Stochastic Oscillator
- PHAR 0.00
- GRAL 0.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.